Table 6.
Demographic, disease classification features and frequency of severe organ system involvement of SSc patients with anti-U1RNP antibody first evaluated during 1972–2007.
| Features | African-American (n= 30) | Caucasian (n= 148) | p-Value |
|---|---|---|---|
| Sex (% female) | 23 (77%) | 122 (82%) | NS |
| Age at onset (mean ± SD) | 34.2 ± 12.3 | 36.7 ± 14.1 | NS |
| Disease duration: Onset to diagnosis (years) ± SD | 3.0 ± 6.9 | 3.9 ± 5.7 | NS |
| HAQ disability index: greatest | 1.1 ± 0.9 | 1.2 ± 0.8 | NS |
| Diffuse disease (%) | 10 (33%) | 29 (20%) | NS |
| Skin (mean maximum TSS ± SD) | 8.5 + 9.0 | 8.5 + 9.9 | NS |
| Vascular | 10/30 (33%) | 60/148 (40%) | NS |
| Skin | 1/30 (3%) | 8/148 (5%) | NS |
| Joint/tendon | 3/30 (10%) | 21/148 (14%) | NS |
| Skeletal muscle | 1/30 (3%) | 4/148 (3%) | NS |
| *GI | 1/24 (4%) | 14/110 (13%) | NS |
| *Pulmonary fibrosis | 12/23 (52%) | 14/122 (11%) | 0.0001 |
| *PAH | 1/21 (5%) | 11/87 (13%) | NS |
| *Heart | 4/24 (17%) | 20/121 (16%) | NS |
| Kidney | 0/30 (0%) | 4/148 (3%) | NS |
SD = standard deviation
HAQ = health assessment questionnaire
*
proportion of patients classified as severe with denominator being total number with objective data that permits severity assessment